- Home
- USEG vs RGLS Comparison
USEG vs RGLS Comparison
Compare USEG & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- RGLS
- Stock Information
- Founded
- USEG 1966
- RGLS 2007
- Country
- USEG United States
- RGLS United States
- Employees
- USEG N/A
- RGLS N/A
- Industry
- USEG Oil & Gas Production
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- USEG Energy
- RGLS Health Care
- Exchange
- USEG Nasdaq
- RGLS Nasdaq
- Market Cap
- USEG 68.6M
- RGLS 74.0M
- IPO Year
- USEG N/A
- RGLS 2012
- Fundamental
- Price
- USEG $1.95
- RGLS $1.31
- Analyst Decision
- USEG Strong Buy
- RGLS Strong Buy
- Analyst Count
- USEG 2
- RGLS 6
- Target Price
- USEG $2.75
- RGLS $10.33
- AVG Volume (30 Days)
- USEG 4.2M
- RGLS 820.1K
- Earning Date
- USEG 03-25-2025
- RGLS 03-20-2025
- Dividend Yield
- USEG N/A
- RGLS N/A
- EPS Growth
- USEG N/A
- RGLS N/A
- EPS
- USEG N/A
- RGLS N/A
- Revenue
- USEG $22,257,000.00
- RGLS N/A
- Revenue This Year
- USEG N/A
- RGLS N/A
- Revenue Next Year
- USEG $12.17
- RGLS N/A
- P/E Ratio
- USEG N/A
- RGLS N/A
- Revenue Growth
- USEG N/A
- RGLS N/A
- 52 Week Low
- USEG $0.81
- RGLS $0.83
- 52 Week High
- USEG $6.40
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- USEG 43.97
- RGLS 53.78
- Support Level
- USEG $2.03
- RGLS $1.22
- Resistance Level
- USEG $2.17
- RGLS $1.60
- Average True Range (ATR)
- USEG 0.22
- RGLS 0.13
- MACD
- USEG -0.05
- RGLS 0.03
- Stochastic Oscillator
- USEG 0.00
- RGLS 50.85
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.